pcNewsWire – BioMark Diagnostics Inc. (CSE: BUX; FSE: 20B; OTC: BMKDF) has closed previously announced private placement of 3,817,127 units, in two closing, at $0.15 per unit for gross proceeds of $572,569.05
Press Release
BioMark Closes Previous Announced Private Placement Offering
Vancouver, British Columbia (FSCwire) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has closed the private placement announced on June 24th 2016.
BioMark closed its first tranche of private placement on March 15, 2016 for proceeds of $408,954 followed by a second tranche of a non-brokered private placement for gross proceeds of $163,615, wherein BioMark issued a total of 3,817,127 units at a price of 15 cents per unit.
Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at 30 cents per share for a period of one year from the closing date of the private placement, subject to an acceleration clause. Finders’ fees were payable on the private placement.
The proceeds of the private placement was used for the continuation of the company’s phase three clinical trials and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.
We seek Safe Harbor.
About BioMark Diagnostics Inc.
BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. For more information please visit the company website at: www.biomarkdiagnostics.com
On Behalf of the Board of Directors
BIOMARK DIAGNOSTICS INC.
“Rashid Ahmed Bux”
CEO and Director
Contact Information
Rashid Ahmed Bux – President & CEO
BioMark Diagnostics Inc.
Tel. 604-282-6567
Email: info@biomarkdiagnostics.com
The CSE has not reviewed, approved or disapproved the content of this press release.
To view this press release as a PDF file, click onto the following link:
public://news_release_pdf/Biomark05082017.pdf
Source: BioMark Diagnostics Inc (CSE:BUX, OTCQB:BMKDF, FWB:20B)
